First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, has launched Ryaltris-AZ Nasal Spray for the treatment of symptoms associated with Allergic Rhinitis (AR) in patients over 12 years of age.
Ryaltris-AZ nasal spray, developed by Glenmark, is a novel fixed-dose combination nasal spray of an antihistamine and a steroid. The spray relieves symptoms of Allergic Rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
Alok Malik, Group Vice President & Business Head, India Formulations said, “Glenmark has been a pioneer in providing access to the latest treatment options for respiratory disease patients in India. We are glad to introduce our brand Ryaltris-AZ, which is clinically studied and cutting-edge, at an affordable cost for patients in the country. Respiratory segment is a key area of focus for Glenmark and the launch of this product will enable us to improve access to allergic rhinitis treatment by providing an effective, convenient, world-class and affordable treatment option to patients in India.”
Glenmark is the first company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg.
According to a study, around 20-30% of the Indian population suffers from Allergic Rhinitis. Moreover, in India, patients have to bear the drug cost on their own and so the price of the drug becomes a major factor that impacts treatment adherence. While the average cost of therapy of top 10 existing brands of the similar drug category is Rs. 365, Glenmark’s Ryaltris has been launched at a breakthrough price of Ryaltric-AZ nasal spray W75 metered doses (MD). This cost is around 52% less as compared to the average price of the Top 10 brands of Rs. 175 per pack of the similar drug category in the market.
Subscribe To Our Newsletter & Stay Updated